NASDAQ:NAGE Niagen Bioscience (NAGE) Stock Price, News & Analysis $4.17 -0.02 (-0.48%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$4.19 +0.02 (+0.48%) As of 05/8/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Niagen Bioscience Stock (NASDAQ:NAGE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Niagen Bioscience alerts:Sign Up Key Stats Today's Range$4.04▼$4.2650-Day Range$4.19▼$5.3352-Week Range$4.04▼$14.69Volume1.79 million shsAverage Volume776,199 shsMarket Capitalization$332.10 millionP/E Ratio19.86Dividend YieldN/APrice Target$15.00Consensus RatingModerate Buy Company Overview Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA. Read More Niagen Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreNAGE MarketRank™: Niagen Bioscience scored higher than 78% of companies evaluated by MarketBeat, and ranked 110th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingNiagen Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialNiagen Bioscience has a consensus price target of $15.00, representing about 259.7% upside from its current price of $4.17.Amount of Analyst CoverageNiagen Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Niagen Bioscience's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth22.73% Earnings GrowthEarnings for Niagen Bioscience are expected to grow by 22.73% in the coming year, from $0.22 to $0.27 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Niagen Bioscience is 19.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Niagen Bioscience is 19.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.64.Price to Book Value per Share RatioNiagen Bioscience has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.52% of the float of Niagen Bioscience has been sold short.Short Interest Ratio / Days to CoverNiagen Bioscience has a short interest ratio ("days to cover") of 9.12.Change versus previous monthShort interest in Niagen Bioscience has recently decreased by 0.79%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNiagen Bioscience does not currently pay a dividend.Dividend GrowthNiagen Bioscience does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.66 News SentimentNiagen Bioscience has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Niagen Bioscience this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for NAGE on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Niagen Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders9.39% of the stock of Niagen Bioscience is held by insiders.Percentage Held by Institutions15.41% of the stock of Niagen Bioscience is held by institutions.Read more about Niagen Bioscience's insider trading history. Receive NAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Niagen Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAGE Stock News HeadlinesWill Niagen Bioscience’s (NAGE) Telehealth NAD+ Push Redefine Its Core Therapeutic Focus?2 hours ago | finance.yahoo.comNiagen Bioscience Announces Participation in Upcoming Investor ConferencesMay 8 at 8:32 AM | businesswire.comThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.May 9 at 1:00 AM | American Alternative (Ad)Niagen Bioscience keeps full-year sales forecast intact as Q1 revenue, profit climbs (updated)May 7 at 7:24 AM | msn.comNiagen (NAGE) Q1 2026 Earnings Call TranscriptMay 6 at 11:51 PM | finance.yahoo.comNiagen Bioscience Earnings Call Highlights Growth PushMay 6 at 9:50 PM | tipranks.comNiagen Bioscience, Inc. Reports First Quarter 2026 Financial ResultsMay 6 at 4:02 PM | businesswire.comNiagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit OfferingMay 4, 2026 | businesswire.comSee More Headlines NAGE Stock Analysis - Frequently Asked Questions How have NAGE shares performed this year? Niagen Bioscience's stock was trading at $6.36 at the beginning of the year. Since then, NAGE shares have decreased by 34.4% and is now trading at $4.17. How were Niagen Bioscience's earnings last quarter? Niagen Bioscience, Inc. (NASDAQ:NAGE) issued its quarterly earnings data on Wednesday, May, 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.01. The business had revenue of $31.47 million for the quarter. Niagen Bioscience had a trailing twelve-month return on equity of 22.68% and a net margin of 14.29%. Who are Niagen Bioscience's major shareholders? Top institutional investors of Niagen Bioscience include SteelPeak Wealth LLC (4.24%), Dimensional Fund Advisors LP (1.34%), OP Asset Management Ltd (0.42%) and Bank of New York Mellon Corp (0.24%). Insiders that own company stock include Frank L Jaksch Jr, Robert N Fried, Brianna Gerber, Ozan Pamir and Kristin Patrick. View institutional ownership trends. How do I buy shares of Niagen Bioscience? Shares of NAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/06/2026Today5/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 NAGE's financial health is in the Red zone, according to TradeSmith. NAGE has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NAGE Previous SymbolNASDAQ:NAGE CIK1386570 WebN/A Phone(310) 388-6706Fax949-419-0294Employees120Year FoundedN/APrice Target and Rating Average Price Target for Niagen Bioscience$15.00 High Price Target$23.00 Low Price Target$10.00 Potential Upside/Downside+259.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$0.21 Trailing P/E Ratio19.86 Forward P/E Ratio18.95 P/E GrowthN/ANet Income$17.38 million Net Margins14.29% Pretax Margin15.10% Return on Equity22.68% Return on Assets16.23% Debt Debt-to-Equity RatioN/A Current Ratio4.61 Quick Ratio3.83 Sales & Book Value Annual Sales$129.42 million Price / Sales2.57 Cash Flow$0.20 per share Price / Cash Flow20.66 Book Value$1.03 per share Price / Book4.05Miscellaneous Outstanding Shares79,640,000Free Float72,165,000Market Cap$332.10 million OptionableN/A Beta2.17 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:NAGE) was last updated on 5/9/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredInvest in SpaceX Before IPOSpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...NXT Wave Research | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
